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Effect of Macrolide Usage on Emergence of Erythromycin-Resistant
Campylobacter Isolates in Chickens
Abstract
In this work we conducted both in vitro and in vivo experiments to examine the development and
mechanisms of erythromycin (Ery) resistance in Campylobacter jejuni and Campylobacter coli. In vitro plating
revealed that both Campylobacter species had similar but low spontaneous mutation frequencies (3 × 10−9 to
−10) for Ery resistance. Chickens infected with C. jejuni or C. coli were subjected to single or multiple
treatments with medicated water containing tylosin (0.53 g/liter), which transiently reduced the level of
Campylobacter colonization but did not select for Ery-resistant (Eryr) mutants in the treated birds. However,
when tylosin was given to the chickens in feed at a growth-promoting dose (0.05 g/kg feed), Eryr mutants
emerged in the birds after prolonged exposure to the antibiotic. The vast majority of the in vitro- and in vivo-
selected Campylobacter mutants with Ery MICs of 8 to 256 μg/ml lacked the known resistance-associated
mutations in the 23S rRNA gene, while the highly resistant mutants (Ery MIC > 512 μg/ml) had the A2074G
mutation in the 23S rRNA gene. Inactivation of CmeABC, a multidrug efflux pump, dramatically reduced the
Ery MIC in all of the examined mutants regardless of the presence of the A2074G mutation. Together, these
results reveal distinct features associated with Ery resistance development in Campylobacter, demonstrate the
significant role of CmeABC in Ery resistance, and suggest that long-term use of a macrolide as a growth
promoter selects for the emergence of Eryr Campylobacter in animal reservoirs.
Disciplines
Genetics and Genomics | Molecular Genetics | Poultry or Avian Science | Veterinary Microbiology and
Immunobiology | Veterinary Preventive Medicine, Epidemiology, and Public Health
Comments
This article is published as Lin, Jun, Meiguan Yan, Orhan Sahin, Sonia Pereira, Yun-Juan Chang, and Qijing
Zhang. "Effect of macrolide usage on emergence of erythromycin-resistant Campylobacter isolates in
chickens." Antimicrobial agents and chemotherapy 51, no. 5 (2007): 1678-1686. doi:10.1128/
AAC.01411-06. Posted with permission.
Authors
Jun Lin, Meiguan Yan, Orhan Sahin, Sonia Pereira, Yun-Juan Chang, Qijing Zhang, and Qijing Zhang
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vmpm_pubs/168
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2007, p. 1678–1686 Vol. 51, No. 5
0066-4804/07/$08.000 doi:10.1128/AAC.01411-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Effect of Macrolide Usage on Emergence of Erythromycin-Resistant
Campylobacter Isolates in Chickens
Jun Lin,1† Meiguan Yan,2† Orhan Sahin,2 Sonia Pereira,2 Yun-Juan Chang,1 and Qijing Zhang2*
Department of Animal Science, University of Tennessee, Knoxville, Tennessee 37996,1 and Department of Veterinary Microbiology and
Preventive Medicine, Iowa State University, Ames, Iowa 500112
Received 11 November 2006/Returned for modification 27 December 2006/Accepted 2 March 2007
In this work we conducted both in vitro and in vivo experiments to examine the development and mecha-
nisms of erythromycin (Ery) resistance in Campylobacter jejuni and Campylobacter coli. In vitro plating revealed
that both Campylobacter species had similar but low spontaneous mutation frequencies (3 109 to <5.41 1010)
for Ery resistance. Chickens infected with C. jejuni or C. coli were subjected to single or multiple treatments
with medicated water containing tylosin (0.53 g/liter), which transiently reduced the level of Campylobacter
colonization but did not select for Ery-resistant (Eryr) mutants in the treated birds. However, when tylosin was
given to the chickens in feed at a growth-promoting dose (0.05 g/kg feed), Eryr mutants emerged in the birds
after prolonged exposure to the antibiotic. The vast majority of the in vitro- and in vivo-selected Campylobacter
mutants with Ery MICs of 8 to 256 g/ml lacked the known resistance-associated mutations in the 23S rRNA
gene, while the highly resistant mutants (Ery MIC > 512 g/ml) had the A2074G mutation in the 23S rRNA
gene. Inactivation of CmeABC, a multidrug efflux pump, dramatically reduced the Ery MIC in all of the
examined mutants regardless of the presence of the A2074G mutation. Together, these results reveal distinct
features associated with Ery resistance development in Campylobacter, demonstrate the significant role of
CmeABC in Ery resistance, and suggest that long-term use of a macrolide as a growth promoter selects for the
emergence of Eryr Campylobacter in animal reservoirs.
Thermophilic Campylobacter spp. (Campylobacter jejuni and
Campylobacter coli) have been recognized as one of the most
commonly detected bacterial pathogens causing human gastro-
intestinal enteritis (5). As an enteric organism, Campylobacter
resides in the gastrointestinal tracts of domestic and wild ani-
mals (17). The majority of human Campylobacter infections are
associated with consumption of undercooked poultry meat as
well as raw milk and contaminated water (17).
Macrolides, such as erythromycin (Ery), represent the drugs
of choice for treating human campylobacteriosis, but fluoro-
quinolones (FQs) are often used for the treatment of enteritis
when a microbiological diagnosis is absent (14, 20). During the
past decades, Campylobacter has become increasingly resistant
to both classes of antibiotics, although the actual resistance
rates vary in different countries (14, 20). The prevalence of
FQ-resistant Campylobacter is high on a worldwide scale, mak-
ing macrolide antibiotics especially important for treatment of
Campylobacter infections in humans (5). However, many stud-
ies have revealed a general trend of rising Ery resistance in
Campylobacter, especially in C. coli (7, 8, 14, 20, 40). The use of
macrolides in food-producing animals as therapeutic or
growth-promoting agents has been considered a factor in the
selection of Ery-resistant (Eryr) Campylobacter (20), but exper-
imental evidence supporting this link is still limited.
Macrolide antibiotics inhibit bacterial growth by binding to
prokaryotic ribosomes and interfering with protein synthesis
(16). Antibiotic modifications, target site alterations, and drug
efflux are the three main mechanisms involved in macrolide
resistance in bacteria (20, 27). However, no evidence has been
reported for macrolide modification in Campylobacter (20, 39).
In both C. jejuni and C. coli, point mutations in the 23S rRNA
gene have been associated with macrolide resistance (14, 19,
23, 25, 33). Specifically, the resistance-associated mutations
occur at base position 2074 (A2074C, A2074G, or A2074T) or
2075 (A2075G or A2075C) or both in the 23S rRNA gene of
Campylobacter. These positions correspond to base positions
2058 and 2059, respectively, in Escherichia coli. There are three
copies of the 23S rRNA gene in C. jejuni and C. coli (15, 37).
Usually all three copies of the 23S rRNA gene are mutated,
but both the wild-type and mutated alleles can coexist in a
single macrolide-resistant mutant (19, 25, 33). A recent finding
(10) demonstrated that modifications in the ribosomal proteins
L4 (G74D) and L22 (insertions at position 86 or 98) also
conferred macrolide resistance in Campylobacter. By inser-
tional mutagenesis, it has been shown that the multidrug efflux
pump CmeABC of C. jejuni contributes to intrinsic and
acquired resistance to macrolides (11, 28, 33). Inhibition of
CmeABC by an efflux pump inhibitor decreased the MICs of
Ery (2- to 512-fold) in various Campylobacter isolates and also
significantly decreased the frequency of emergence of Eryr C.
jejuni mutants (34).
Macrolides, such as tylosin and spiramycin, are used in
chickens as therapeutic/prophylactic agents for the control of
chronic respiratory diseases caused by mycoplasmas and as
subtherapeutic agents for improving growth rates and feed
efficiency in the United States (18, 20). Since chickens are
frequently colonized by Campylobacter in the intestinal tract
and since contaminated poultry meat is considered a significant
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source of food-borne campylobacteriosis in humans, it has
been a concern whether exposure of chickens to therapeutic or
subtherapeutic doses of macrolides promotes the emergence
of macrolide-resistant Campylobacter, as is reported for the
emergence of FQ resistance (22, 32, 35). To address this con-
cern, we conducted in vitro and in vivo studies to examine the
frequencies of emergence of Eryr C. jejuni and C. coli under
the selection pressure of macrolide usage. In addition, we
investigated the resistance mechanisms associated with Ery
resistance in Campylobacter.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Two C. jejuni strains, S3B (32) and
ATCC 700819 (NCTC 11168), and four C. coli strains, RN14B, MR32D, AW-
II-35, and AW-II-37, were used in this study. All these strains are susceptible to
Ery, with Ery MICs of 0.125 g/ml for AW-II-35 and AW-II-37 and 2 g/ml for
S3B, 700819, RN14B, and MR32D. The Campylobacter strains were grown rou-
tinely on Mueller-Hinton (MH) agar plates or in MH broth at 42°C under
microaerobic conditions. Campylobacter-specific growth supplements and selec-
tive agents (Oxoid) were added to the media when needed. When required, the
MH media were also supplemented with various amounts of Ery.
Frequencies of emergence of Eryr C. jejuni and C. coli in vitro. C. jejuni and C.
coli cultures were grown in antibiotic-free MH broth to the late logarithmic
phase. The cultures were plated in duplicate on antibiotic-free MH agar plates
and Ery-containing plates (2, 4, or 8 g/ml). The plates were incubated for 2 days
microaerobically at 42°C. The frequency of Ery resistance was calculated as the
ratio of the numbers of CFU on Ery-containing plates to the CFU on Ery-free
plates. The experiment was repeated three times.
Antibiotic susceptibility test. MICs of antibiotics were tested using the agar
dilution method as recommended by the CLSI (formerly NCCLS) (13). For
quality control, C. jejuni ATCC 33560 and the quality control range for the Ery
MIC of 0.25 to 2 g/ml were used in this study. According to the breakpoints
recommended by CLSI (13), Ery MICs of 8 g/ml and 32 g/ml indicate
susceptibility and resistance, respectively. Ery was purchased from Sigma Chem-
ical Co., St. Louis, MO.
Sequence analysis of the 23S rRNA gene. The 23S rRNA gene sequences of C.
jejuni and C. coli were amplified by PCR with gene-specific primers (5-GTAA
ACGGCGGCCGTAACTA-3 and 5-GACCGAACTGTCTCACGACG-3)
(25). The PCR conditions were as follows: 94°C for 5 min; 94°C for 30 s, 52°C for
30 s, and 72°C for 40 s for 35 cycles; and a final extension at 72°C for 10 min. The
amplified PCR products were purified with the QIAquick PCR purification kit
(QIAGEN) prior to sequencing. DNA sequences were determined in the DNA
facilities at Iowa State University and the University of Tennessee. Sequence
analysis was performed using Omiga 2.0 software (Oxford Molecular Ltd.).
Immunoblotting analysis of CmeABC expression. To examine if CmeABC was
overexpressed in the Eryr isolates, the CmeA, CmeB, and CmeC proteins of Eryr
isolates S3BE2-2 and S3BE4-3 (Ery MIC  256 and 128 g/ml, respectively; no
mutation in the 23S rRNA gene) as well as their parent strain, S3B, were
analyzed by immunoblotting with antibodies specific for CmeA, CmeB, and
CmeC as described previously (28).
Insertional mutagenesis of the cmeB gene in various isolates. Natural trans-
formation was used to construct the isogenic cmeB mutants of various Campy-
lobacter isolates as described previously (4). Genomic DNA of 11168B
(cmeB::kan) was used as the donor DNA in the transformation experiments,
while various Campylobacter isolates with different levels of resistance to Ery
were used as the recipient strains. Natural transformation was performed with a
biphasic method as described by Wang and Taylor (43). Transformants were
selected on plates containing 30 g/ml of kanamycin. The insertion of the
kanamycin cassette into the cmeB gene of each recipient isolate was confirmed
by PCR as described previously (28).
Treatment of Campylobacter-colonized chickens with medicated water contain-
ing tylosin. A chicken colonization model was used to assess the effect of high-
dose tylosin treatment on the emergence of Eryr mutants in Campylobacter. For
this purpose, day-old broiler chickens (Ross  Cobb) were purchased from a
commercial hatchery and randomly assigned to multiple groups (10 to 15 birds
per group). Each group of chickens was housed in a sanitized wire floor cage and
provided with nonmedicated feed ad libitum. Prior to inoculation with Campy-
lobacter, all birds were confirmed to be free of Campylobacter by culturing cloacal
swabs. Each Campylobacter strain or a mixture of two strains was used to inoc-
ulate two groups of chickens (107 CFU/bird). Five days after the inoculation, one
of the two groups inoculated with the same culture (or mixture) was treated with
tylosin (Tylan; soluble; Elanco Animal Health), while the other group was un-
treated and used as a control for the treated group. Each tylosin treatment was
given to the chickens in drinking water for three consecutive days according to
the dose (0.53 g/liter) approved for commercial poultry production in the United
States. During the treatment, only medicated water was given to the birds to
ensure enough consumption to provide tylosin at 110 mg/kg of body weight per
day as indicated by the drug label. Cloacal swabs were collected from the
chickens before and after tylosin treatment until the end of each experiment.
Each swab was diluted serially in MH broth, and each dilution was plated onto
two different types of MH plates: one containing Campylobacter-specific selective
agents and growth supplements (SR084E and SR117E; Oxoid) to recover the
total Campylobacter populations and the other containing 8 g/ml Ery in addition
to the same selective agents and supplements to recover the Campylobacter
populations that were considered not susceptible to Ery. Campylobacter colonies
were counted following 48 h of incubation at 42°C under microaerobic condi-
tions. At each sampling time, 10 to 15 colonies (from different chickens) were
collected from each group for MIC testing using the standard agar dilution
method (13). Three independent experiments were conducted in total. In exper-
iment A, C. jejuni S3B and 700819 were used for infecting chickens; in experi-
ment B, the two groups of chickens were inoculated with a mixture of C. coli
strains AW-II-35 and AW-II-37; and in experiment C, the chickens were inoc-
ulated with C. jejuni 700819 but the treatment group was treated three times with
tylosin at a weekly interval.
Feeding of Campylobacter-colonized chickens with tylosin at a low dose. Two
independent experiments were conducted with chickens using tylosin at the dose
used for growth promotion. In each experiment, day-old broiler chickens were
obtained from a commercial hatchery and the birds were randomly assigned to
two groups (9 to 11 birds per group). Birds in the control group received
nonmedicated feed without any antibiotic additives. Chickens in the treatment
group received the same feed but supplemented with tylosin (Elanco Animal
Health). The nonmedicated feed and the tylosin-containing feed were prepared
by the feed mill in the Johnson Animal Research and Teaching Unit at the
University of Tennessee. Instructions on the drug label were followed in the
preparation of the medicated feed for growth promotion in chickens. The final
concentration of tylosin in the feed was 50 mg/kg, which is an approved dose for
growth promotion in poultry production in the United States. Since a withdrawal
period is not required for tylosin used for growth promotion in chickens (6), the
birds in the treatment group were given the medicated feed for the entire 41 days
of the experiment. All of the birds were negative for Campylobacter prior to
Campylobacter inoculation, as determined by culturing cloacal swabs. In the first
experiment, each chicken was inoculated with a fresh culture of approximately
107 CFU of C. jejuni ATCC 700819 via oral gavage at 3 days of age. After the
inoculation, cloacal swabs were collected from each chicken at 6, 13, 20, 27, 34,
and 41 days of age. Isolation of Campylobacter and differential plating for enu-
merating the proportion of the mutant colonies were conducted as described for
the water medication study. In addition, individual colonies were collected from
Ery-free plates for each chicken and were used for MIC tests. In the second
experiment, the inoculation of chickens with C. jejuni ATCC 700819 was at 17
days of age and cloacal swabs were collected from the chickens at 20, 27, 34, and
41 days of age. The reason for using two different inoculation dates in the two
experiments was to measure if the duration of exposure to the growth promoter
affects the emergence of Eryr Campylobacter. In addition, a distinct characteristic
of C. jejuni colonization in poultry is that this organism is not detected in
chickens less than 2 to 3 weeks of age under commercial broiler production
conditions. Thus, inoculation of birds with C. jejuni at 17 days of age in the
second experiment should allow us to measure the impact of the use of tylosin as
a growth promoter on the development of Ery resistance in Campylobacter under
conditions similar to commercial production. Multiple isolates with different Ery
MICs were analyzed by PCR and pulsed-field gel electrophoresis (PFGE) to
confirm their genetic identities. The PCR was done using primers F3 and R3,
specific for the cmp gene encoding the major outer membrane protein, and the
PFGE was performed using KpnI as described previously by Huang et al. (24).
Detection limit and statistical analysis. In all chicken experiments, the detec-
tion limit of the plating methods is approximately 100 CFU/g of feces. When no
Campylobacter colonies were detected in a chicken, it was considered negative
and arbitrarily assigned the number 0 for the purpose of calculating means and
statistical analysis. Student’s t test was used to examine the significance of
differences in Campylobacter colonization levels (log transformed CFU/g feces)
at each sampling point between the tylosin-treated and nontreated groups inoc-
ulated with the same Campylobacter strain. A P value of 0.01 was considered
significant.
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RESULTS
Frequencies of emergence of Eryr Campylobacter mutants in
vitro. To determine the frequencies of emergence of Ery re-
sistance in C. jejuni and C. coli in vitro, two C. jejuni strains
(S3B and 700819) and two C. coli strains (RN14B and
MR32D) grown in antibiotic-free MH broth were plated on
MH agar plates containing 4 or 8 g/ml erythromycin. As
shown in Table 1, the frequencies of emergence of Ery resis-
tance in both Campylobacter spp. were between 3  109 and
1010 as measured by a single-step selection. There were no
significant differences (P  0.7135) between the frequencies of
mutant emergence measured with 4 g/ml or 8 g/ml of eryth-
romycin (Table 1). In addition, there were no significant dif-
ferences in the mutant emergence frequencies between C. coli
and C. jejuni regardless of the concentrations of erythromycin
used on the plates. All of the examined mutants had Ery MICs
of 8 to 256 g/ml (Table 2). These findings indicate that
the emergence of spontaneous Eryr mutants in Campylobacter
under in vitro culture conditions is at a low frequency.
Effect of tylosin treatment on the emergence of Eryr Campy-
lobacter in chickens. To determine if tylosin treatment influ-
ences the development of macrolide resistance in Campy-
lobacter, broiler chickens were first infected with C. jejuni or
C. coli and then treated (single or multiple times) with tylosin
administered in drinking water at the dose (0.53 g/liter) rec-
ommended for therapeutic use in commercial poultry produc-
tion in the United States. In the first experiment, the chickens
inoculated with C. jejuni (S3B or 700819) were quickly colo-
nized and shed the organism at a level between 105 and 107
CFU/g feces before the initiation of tylosin treatment (Fig.
1A). Two days after the initiation of the tylosin treatment, the
number of colonized chickens decreased drastically, with
Campylobacter detectable only in a few chickens. The few
chickens that remained colonized on days 2 and 4 after initia-
tion of the tylosin treatment shed significantly lower numbers
of organisms in the feces than those in the nontreated groups
(Fig. 1A). However, the number of colonized chickens and the
level of colonization recovered and reached the levels for the
nontreated groups after cessation of the treatment (Fig. 1A).
Nontreated chickens remained colonized and shed Campy-
lobacter at approximately 105 to 106 CFU/g feces throughout
the study (Fig. 1A). During the entire experiment, no Campy-
lobacter colonies were observed on plates containing 8 g/ml
Ery. In addition, representative colonies (10 isolates/sample/
group) collected from the chickens were tested by the agar
dilution method for MICs of erythromycin. All of the isolates
had the same Ery MIC (2 g/ml) as that of the parent strains,
S3B and 700819, further confirming that the single tylosin
treatment did not select for Eryr Campylobacter. In the second
experiment, the chickens were infected with a mixture of two
strains of C. coli (AW-II-35 and AW-II-37) and then treated
with tylosin. As shown in Fig. 1B, the treatment did not erad-
icate C. coli from the chickens despite a significant reduction in
the level of colonization during the treatment (P  0.01). On
day 3 after the initiation of tylosin treatment, only 20% of the
birds shed detectable levels of Campylobacter in feces; how-
ever, 100% of the birds became shedders again on the next
sampling day. No Eryr mutants were detected in any of the
TABLE 1. Frequency of emergence of Eryr Campylobacter in vitro under different selection pressures
Ery concn
(g/ml)
Frequencya for strain:
S3B 700819 RN14B MR32D
4 (3.0  3.2)  109 5.4  1010 (1.1  1.2)  109 (4.9  2.2)  1010
8 (1.2  0.9)  1010 5.4  1010 (5.6  2.5)  1010 (4.5  1.6)  1010
a Means of three independent experiments  standard deviations.
TABLE 2. Ery MICs and mutations in various Campylobacter
strains and mutants
Strain Background Ery MIC
a
(g/ml)
Mutation in
23S rRNA
Ery MIC of the
cmeB mutant
(g/ml)b
Wild-type
strains
700819 C. jejuni 2 None 0.125
S3B C. jejuni 2 None 1
RN14B C. coli 2 None 0.125
MR32D C. coli 2 None NDd
AW-II-35 C. coli 0.125 None ND
AW-II-37 C. coli 0.125 None ND
In vitro-selected
mutants
S3BE2-2 S3B 256 None 0.125
S3BE4-1 S3B 32 None ND
S3BE4-2 S3B 32 None ND
S3BE4-3 S3B 128 None ND
S3BE8-1 S3B 256 None ND
RN14BE4-2 RN14B 8 A2074Gc 0.125
RN14BE4-3 RN14B 32 None 0.125
RN14BE8-1 RN14B 32 None ND
RN14BE8-2 RN14B 32 None ND
RN14BE8-3 RN14B 32 None ND
MR32DE4-1 MR32D 8 None ND
MR32DE8-1 MR32D 32 None ND
In vivo-selected
mutants
1 700819 8 None 0.250
2 700819 8 None 0.125
3 700819 32 None 0.250
4 700819 	512 A2074G 32
5 700819 	512 A2074G 32
6 700819 	512 A2074G 32
7 700819 8 None 0.250
8 700819 16 None 0.250
9 700819 32 None 0.250
10 700819 8 None 0.125
11 700819 8 None 0.250
12 700819 8 None 0.250
a Determined by the agar dilution method.
b Each cmeB mutant was generated from the corresponding isolate by inser-
tional mutagenesis.
c Present in one of the three copies of the 23S rRNA gene.
d ND, no mutagenesis of cmeB was done in the isolate.
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treated chickens by either the differential plating method or
the MIC test. The findings from the C. coli experiment were
consistent with the results from the first experiment with C.
jejuni and indicated that a single tylosin treatment did not
select for macrolide-resistant Campylobacter in chickens. In the
third experiment, the chickens inoculated with C. jejuni 700819
received three tylosin treatments at a weekly interval. As
shown in Fig. 1C, the colonization level of 700819 dropped
significantly (P  0.01) during the first treatment but returned
to the level of the nontreated controls afterward and persisted
during the subsequent treatments. Despite the three treat-
ments, no Eryr mutants were detected in any of the treated
chickens by both differential plating and MIC testing. To-
gether, these results indicated that short-term treatment of
Campylobacter-infected chickens with tylosin at a high dose did
not result in the selection of Eryr Campylobacter regardless of
the number of treatments or the species of Campylobacter
treated.
FIG. 1. Effect of tylosin treatment on the colonization of Campylobacter in chickens. (A) Chickens were inoculated with C. jejuni 700819 and
S3B, respectively. Two (700819-trt and S3B-trt) of the groups received a single treatment with tylosin, while the other two groups (700819-con and
S3B-con) were nontreated controls. (B) Two groups of chickens were inoculated with a mixture of C. coli strains AW-II-35 and AW-II-37. One
group (C.coli-trt) received a single treatment with tylosin, while the other (C.coli-con) served as a nontreated control group. (C) Chickens were
infected with C. jejuni 700819. One group (700819-con) served as the nontreated control, while the other group (700819-trt) received three tylosin
treatments at a weekly interval. The arrows in panel C indicate the starting day of each treatment. In all three experiments (A to C), tylosin was
given in drinking water (0.53 g/liter) for three consecutive days for each treatment. Each bar represents the arithmetic mean  standard deviation
of the mean log10 CFU/g feces in each group. The CFU in individual chickens were converted to log10 units before calculating the arithmetic means.
For the two groups inoculated with the same strain, the means on the same sampling day labeled with different letters are significantly different
(P  0.01).
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Emergence of Eryr Campylobacter upon long-term exposure
to tylosin at a low dose. To determine if long-term use of
tylosin as a growth promoter affects the development of Ery
resistance in C. jejuni, strain 700819 was inoculated into chick-
ens that received either nonmedicated feed or feed supple-
mented with tylosin at a dose (50 mg/kg feed) used for growth
promotion. In the first experiment, the chickens were inocu-
lated with Campylobacter at 3 days of age. All chickens, includ-
ing the ones with the medicated feed, were colonized by C.
jejuni on day after inoculation (DAI) 3 (Fig. 2A). The shedding
level of Campylobacter in feces was consistently higher (up to
2.4 log10 units) in the chickens given nonmedicated feed than
in those given the tylosin-containing feed, except that on DAI
38 the shedding levels of C. jejuni for the nonmedicated group
were slightly lower (but the difference was not statistically
significant: P  0.3) than those for the medicated group (Fig.
2A). No Eryr C. jejuni mutants were detected in the nonmedi-
cated group throughout the study. However, in the group fed
with tylosin, Eryr mutants were detected in the chickens on
DAI 31 and 38 (Fig. 3A). In the second experiment, the chick-
ens were inoculated with C. jejuni 700819 at 17 days of age.
Similar to the first experiment, the level of Campylobacter
colonization in the medicated group was consistently lower
(the differences were significant on DAI 10 and 24: P  0.01)
than that in the nonmedicated group (Fig. 2B). In the medi-
cated group, the mutant colonies growing on the Ery plates
were detected on DAI 17 and 24 (Fig. 3B).
Differential plating, in which the Eryr Campylobacter mu-
tants and the total Campylobacter colonies in each swab sample
were simultaneously enumerated by using two different types
of plates, revealed the dynamics of emergence of Eryr Campy-
lobacter in the chickens. In the first experiment, no birds
showed Eryr Campylobacter mutants at DAI 3, 10, 17, and 24
but, on DAI 31, the mutant populations had become dominant
in seven of the nine chickens given the tylosin-medicated feed
(Fig. 3A). On DAI 38, the mutant population varied in indi-
vidual chickens, ranging from 12 to 100% (Fig. 3A). From the
samples collected from the tylosin-treated chickens on DAI 31
and 38, 27 Campylobacter isolates from individual chickens
were randomly selected for MIC testing. Among the 27 isolates
examined, 10 isolates displayed an Ery MIC of 	512 g/ml, 2
isolates showed an Ery MIC of 32 g/ml, 3 isolates had an Ery
MIC of 8 g/ml, and the rest had Ery MICs of8 g/ml. In the
second experiment, Campylobacter mutants were not detected
on Ery-containing (8 g/ml) plates on DAI 3 and 10 but ap-
peared on DAI 17 and 24 in the group fed with tylosin (Fig.
3B). Thirty-five isolates collected on DAI 17 and 24 from the
FIG. 2. Levels of Campylobacter colonization in chickens given
tylosin at a growth-promoting dose in feed. In both experiments (A
and B), the chickens were inoculated with C. jejuni 700819. One group
received nonmedicated feed (control), while the other (treatment)
received medicated feed containing tylosin (50 mg tylosin/kg feed). In
both experiments, the chickens in the treatment groups were given the
medicated feed during the entire experiment (41 days). For panel A,
the birds were inoculated with C. jejuni at 3 days of age, while for panel
B the chickens were inoculated at 17 days of age. Each bar represents
the mean log10 CFU/g feces  standard deviation in each group.
Different letters above the bars of each sampling day denote significant
differences (P  0.01).
FIG. 3. Development of Eryr C. jejuni in individual chickens fed
with tylosin (50 mg tylosin/kg feed) in two different experiments (A and
B). See the legend of Fig. 2 for the details of the treatment. Each solid
circle represents the percentage of the mutant population in each
chicken, which was determined by differential plating using plates
containing 8 g/ml of Ery. The mean of each group is indicated by a
horizontal bar.
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tylosin-treated group were examined for Ery MICs, among
which 4 showed an Ery MIC of 16 g/ml, 13 had an Ery MIC
of 8 g/ml, and the rest had an Ery MIC of 8 g/ml. In both
experiments, no Eryr Campylobacter mutants from the non-
treated chickens were detected by differential plating and the
MIC tests (data not shown). In addition, representative Eryr
isolates derived from the tylosin-fed chickens were analyzed by
PCR (for the cmp gene) and PFGE, which revealed that the
cmp gene sequence and the KpnI restriction patterns of the
mutants were identical to those of strain 700819 (data not
shown), indicating that the mutants were derived from the
parent strain.
Resistance mechanisms associated with Eryr mutants. Both
in vitro- and in vivo-selected mutants with different Ery MICs
were chosen for 23S rRNA gene sequence analysis and cmeB
mutation (Table 2). None of the in vitro-selected mutants with
Ery MICs ranging from 8 to 256 g/ml carried the resistance-
associated mutations in the 23S rRNA gene, except for the C.
coli derivative RN14BE4-2 (Ery MIC  8 g/ml), which har-
bored the A2074G point mutation in the 23S rRNA gene
(Table 2). According to the sequence result, it appeared that
the A2074G mutation was present in only one of the three
copies of the 23S rRNA gene in RN14BE4-2, because the
sequence chromatogram showed double peaks in the same
position where the G peak was 50% shorter than the A peak.
For the in vivo-selected mutants, all of the 10 highly resistant
mutants (Ery MIC 	 512 g/ml) displayed the specific
A2074G point mutation in the 23S rRNA gene but none of the
18 examined mutants with Ery MICs from 8 to 32 g/ml
showed point mutations in the gene (partly shown in Table 2).
Inactivation of cmeB in the Campylobacter mutants dramati-
cally reduced the resistance to Ery (Table 2). For the mutants
without any mutations in the 23S rRNA gene, inactivation of
cmeB reversed the acquired Ery resistance to a level that was
even below the wild-type MIC (Table 2), indicating that the
CmeABC efflux pump plays an essential role in maintaining
the acquired Ery resistance in these mutants. For those in
vivo-selected isolates with the A2074G point mutation, inacti-
vation of cmeB reduced the resistance from 	512 to 32 g/ml.
To determine if cmeABC was overexpressed in the Eryr mu-
tants, we compared the protein levels of CmeABC in several
Eryr mutants and their wild-type strain using immunoblotting,
and no obvious differences in CmeABC expression were ob-
served (data not shown). In addition, MIC tests indicated
that the Eryr mutants did not show cross-resistance to non-
macrolide antibiotics, including enrofloxacin, oxytetracycline,
florfenicol, and penicillin (data not shown).
DISCUSSION
Results from this study revealed several distinct features
associated with Ery resistance development in Campylobacter.
Firstly, the in vitro plating results (Table 1) using single-step
selection and the in vivo findings from the treatment with
tylosin suggest that both C. jejuni and C. coli have extremely
low rates of spontaneous mutation to Eryr (Table 1), which is
in contrast to the emergence of FQ resistance in Campy-
lobacter (21, 47). Secondly, it appears that the acquisition of
Ery resistance in Campylobacter involves a stepwise process
and requires prolonged exposure to the selection pressure.
This conclusion is supported by the fact that Eryr mutants
emerged in the chickens fed with tylosin for an extended pe-
riod (Fig. 3) but were not detected in the chickens treated with
tylosin-medicated water for short periods. The conclusion is
also supported by the finding that the Eryr mutants obtained by
a single-step selection in vitro had an Ery MIC of 256 g/ml
and that the majority of them lacked the resistance-associated
mutations in the 23S rRNA gene (Table 2), which suggests that
emergence of high-level Ery resistance (MIC 	 512) may re-
quire multiple mutation steps. The low frequency of sponta-
neous mutation of Campylobacter to macrolide resistance and
the need for prolonged exposure for resistance development
may explain the relatively low prevalence of Eryr Campy-
lobacter compared with FQ-resistant Campylobacter.
An interesting finding of this study is that treatment of
chickens with a high dose of tylosin in drinking water did not
select for Eryr mutants. For the water medication, the chickens
were given a high dose of tylosin for three consecutive days
during each treatment. Neither single nor multiple short-term
water medications selected for Eryr mutants in the chickens,
even though the treatments transiently reduced the number of
Campylobacter in the intestinal tracts of chickens (Fig. 1). In
fact, all of the tested isolates from the water medication study
had the same Ery MICs as the parent strains, indicating that
there were no changes in the susceptibility of Campylobacter to
Ery before and after the water medications. These findings
indicate that, under the experimental conditions used in this
study, no Eryr Campylobacter was selected by the water med-
ication. However, these results may not be used to predict
resistance development on poultry farms, where each flock
contains a large number of birds and can be infected by mul-
tiple strains of Campylobacter, which may respond differently
to water medication with tylosin. Nevertheless, findings from
this study suggest that the probability of selection for Ery
resistance in Campylobacter is low when tylosin is given to
chickens for a short period of time.
This study clearly showed that use of tylosin as a growth
promoter resulted in the emergence of Eryr C. jejuni in the
chickens under laboratory conditions (Fig. 3). During the ex-
periments, the chickens were fed with a low dose of tylosin for
the entire period (41 days). Eryr mutants were not detected
during the first 2 to 4 weeks of exposure and were observed
only after an extended period of exposure to the antibiotic
(Fig. 3). The lack of Eryr mutants during the early weeks is
consistent with the result of the water medication experiments,
in which single or multiple short-term treatments did not select
for Eryr Campylobacter. Together, these results suggest that
continuous exposure to a macrolide for an extended period is
required for Ery resistance development in Campylobacter.
Thus, the different outcomes in resistance development be-
tween the two types of treatments (therapy or growth promo-
tion) are likely due to the difference in the lengths of exposure,
instead of the routes of administration or the doses of tylosin
used in the treatments. However, we cannot exclude the pos-
sibility that the drug doses and exposure time interact with
each other in the selection of Ery resistance in Campylobacter.
This possibility remains to be determined in future studies. In
this study, we evaluated only the response of C. jejuni to the
growth-promoting dose of tylosin because C. jejuni represents
the most important Campylobacter species associated with hu-
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man food-borne disease. We speculate that C. coli would also
behave similarly when exposed to tylosin at a low dose for a
prolonged period of time. This possibility remains to be deter-
mined in future studies.
Various antibiotics, such as macrolides and tetracycline,
have been used as growth promoters to improve average daily
weight gain and feed efficiency in food-producing animals (18,
36). Use of antibiotics as growth promoters in animal feed is
considered a great selection pressure for antibiotic resistance
since bacteria are exposed to subtherapeutic levels of drugs
over a long period of time. The association between use of a
growth promoter and resistance development has been docu-
mented in several circumstances (45). For example, a strong
link between use of avoparcin and macrolides as growth pro-
moters in poultry and pigs and resistance development in fecal
enterococci was demonstrated in Denmark, Finland, and Nor-
way (2, 9). Another study also reported a clear effect of tylosin
used as a growth promoter on the development of Eryr entero-
cocci and staphylococci in pigs (1). The same study also re-
vealed that the effect of tylosin on Ery resistance was immedi-
ate in enterococci but was gradual in staphylococci, suggesting
that different bacterial pathogens may respond differently to
tylosin in terms of resistance development (1). In Denmark,
ending the use of antimicrobial growth promoters (including
tylosin) significantly reduced the prevalence of antibiotic-resis-
tant enterococci in chickens and pigs and Eryr Campylobacter
in pigs (46), providing compelling evidence for the role of
antimicrobial growth promoters in selecting resistant bacteria.
Our finding that long-term use of tylosin at a subtherapeutic
concentration selects for Eryr Campylobacter in chickens (Fig.
3) is consistent with these previous observations. However, this
study was conducted in a laboratory environment using a small
number of chickens, which may not fully represent the produc-
tion conditions on poultry farms. Thus, the findings from this
study should be interpreted cautiously, considering the com-
plexity of antibiotic resistance development on animal farms,
which is influenced by multiple factors including antimicrobial
usage, animal species, production environments, and the ge-
netic backgrounds of bacterial species as well as management
practices.
Previous studies by us and other researchers (22, 31, 35)
showed that C. jejuni is highly mutable in response to FQ
treatment and that FQ-resistant mutants occurred in FQ-
treated chickens rapidly after the initiation of treatment. The
feature of FQ resistance development in response to antibiotic
treatment is in clear contrast to the emergence of Eryr Campy-
lobacter in poultry, and this difference may be due to the
dissimilarity in the mode of action and resistance mechanisms.
Macrolide antibiotics target bacterial ribosomes and inhibit
protein synthesis, while FQs target DNA gyrase and inhibit
DNA replication and transcription. For FQ resistance, a sin-
gle-step mutation in GyrA is sufficient for conferring high-level
resistance, while a stepwise process may be required for the
development of Ery resistance. It is also possible that the
gyrase gene in Campylobacter is intrinsically more mutable
than the 23S rRNA gene, leading to a higher frequency of
emergence of FQ-resistant mutants than of Eryr mutants.
Previous studies indicate a general trend toward greater
prevalence of macrolide-resistant C. coli than of macrolide-
resistant C. jejuni in both animals and humans (7, 8, 30, 41).
However, our results revealed that there appear to be no
significant differences in the frequencies of emergence of Eryr
mutants between C. jejuni and C. coli, which was shown by both
in vitro and in vivo experiments, and suggested that C. coli may
not be intrinsically more mutable than C. jejuni with regard to
developing macrolide resistance. The difference in the ob-
served prevalence of macrolide resistance between C. jejuni
and C. coli isolated from food-producing animals may be re-
lated to their particular association with certain species of host
animals and the production practices associated with the host
animals. For example, C. coli is the predominant Campy-
lobacter species in pigs and turkeys (3, 26, 29, 44) and macro-
lide antibiotics are used more often in these two species than
in chickens. In contrast, C. jejuni is predominantly associated
with chickens, for which macrolides are less frequently used for
growth promotion (12). In addition, the production cycle for
broiler chickens is significantly shorter than that for turkeys or
pigs, implying that broiler chickens are less exposed to antibi-
otics than turkeys and pigs. It should also be pointed out that
cross-resistance between lincosamides (e.g., clindamycin and
lincomycin) and macrolides has been reported with Campy-
lobacter (29, 42). Thus, use of antibiotics of the lincosamide
class in animal production may also affect the emergence and
prevalence of Eryr Campylobacter.
Interestingly, all of the in vivo-selected mutants that dis-
played high-level Ery resistance (MIC 	 512 g/ml) contained
the A2074G mutation in all three copies of the 23S rRNA
gene, which is different from the previous finding that the
predominant mutation detected in Campylobacter mutants
with high-level Eryr is A2075G (20). Gibreel et al. (19) has
suggested that the reason that the A2074G mutation occurs at
a very low frequency among different Eryr C. jejuni isolates is
likely the negative effect of the mutation on the growth rate of
Campylobacter. However, the growth rate of the in vivo-se-
lected Eryr mutants with the A2074G mutation from this study
appeared to be similar to that of the parent strain (ATCC
700819), as indicated by the sizes of the colonies over a period
of 72 h (data not shown). Given the evidence that none of the
sequenced Eryr C. jejuni isolates exhibited the A2075G muta-
tion, it is likely that emergence of a specific point mutation that
confers high-level Eryr is dependent on the genetic features of
a strain, the environment in which the mutation is selected,
and/or specific macrolide agent used for selection.
Recently the involvement of the CmeABC efflux system in
macrolide resistance has been examined by several research
laboratories (11, 19, 33). It is a general notion that CmeABC is
linked to low and intermediate resistance to erythromycin,
while the 23S rRNA mutations can confer a high level of
erythromycin resistance (33, 38). Another recent study con-
cluded that 23S rRNA mutations and CmeABC work together
in C. coli to confer high-level macrolide resistance (11). In this
study, the Eryr mutants (except for RN14BE4-2) obtained by a
single-step selection did not have mutations at position 2074 or
2075 in the 23S rRNA gene and had erythromycin MICs be-
tween 8 g/ml and 256 g/ml (Table 2). Thus, the 23S rRNA
mutations were not the major contributor to the acquired re-
sistance in these strains. At present we don’t know if there are
any mutations in ribosomal proteins L4 (G74D) and L22 of the
mutants as reported by Cagliero et al. (10). Regardless of the
presence of target mutations, inactivation of cmeB greatly re-
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duced the resistance to Ery (Table 2), indicating that CmeABC
is a significant player in maintaining the acquired resistance to
Ery. Interestingly, the contribution of CmeABC to the in-
creased Ery resistance is not due to overexpression of this
efflux pump because immunoblotting demonstrated that both
the parent strain (S3B) and its mutants produced similar
amounts of the efflux proteins. In many of the mutants, inac-
tivation of CmeB led to the decrease of Ery MIC to a level that
was even below that of the wild-type strains (Table 2). This can
be explained by the known role of CmeABC in the intrinsic
resistance to various antibiotics (28). Thus, the loss-of-function
mutation in CmeB is expected to reduce both the intrinsic and
acquired resistance of Campylobacter to macrolides. The new
findings from this work further confirm that CmeABC is a
significant player in conferring Ery resistance in Campy-
lobacter.
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